What is the Cohance Lifesciences PE ratio today?
Cohance Lifesciences' PE ratio is 173.4 at the 29 October 2026 close (₹481.35 a share): a market capitalisation of ₹18,416 crore divided by consolidated net profit attributable to shareholders of ₹106 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹179 crore) it is 102.8. These four quarters include net exceptional items of −₹21.4 crore (one-off charges reported separately), so the ratio on recurring profit would differ.
What is the Cohance Lifesciences PB ratio (price to book value)?
Cohance Lifesciences' price-to-book (PB) ratio is 4.71 at the 29 October 2026 close: a market capitalisation of ₹18,416 crore divided by shareholders' equity (book value) of ₹3,911 crore on 31 March 2026. That is a book value of ₹102.23 per share against a share price of ₹481.35.
What is the Cohance Lifesciences ROE and ROCE?
In FY26, Cohance Lifesciences' return on equity (ROE) was 6.4% and its return on capital employed (ROCE) was 6.2%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 14.3% and ROCE 12.4%.
What is the Cohance Lifesciences market cap?
Cohance Lifesciences' market capitalisation was ₹18,416 crore at the 29 October 2026 close: 38.26 crore shares at ₹481.35 each.
Is Cohance Lifesciences debt free?
No. Cohance Lifesciences had borrowings of ₹170 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.04. Its cash and current investments were ₹326 crore, so it held net cash of ₹156 crore.
What is the Cohance Lifesciences EPS?
Cohance Lifesciences' basic earnings per share (EPS) were ₹4.69 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹2.78.
What is the Cohance Lifesciences debt to equity ratio?
Cohance Lifesciences' debt-to-equity ratio was 0.04 on 31 March 2026: borrowings of ₹170 crore against total equity of ₹4,034 crore. A year earlier, on 31 March 2025, it was 0.04.
What is the Cohance Lifesciences book value per share?
Cohance Lifesciences' book value per share was ₹102.23 on 31 March 2026: shareholders' equity of ₹3,911 crore divided by the 38.26 crore shares in issue. The share price at the 29 October 2026 close was ₹481.35.
When are the Cohance Lifesciences next results?
Cohance Lifesciences will announce its Q2 FY27 results (July–September 2026) on Friday, 6 November 2026, the date of the board meeting it has notified to the exchanges.
What is the Cohance Lifesciences net worth?
Cohance Lifesciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹3,911 crore on 31 March 2026, up 130.5% from ₹1,697 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹18,416 crore at the 29 October 2026 close.
What is the Cohance Lifesciences promoter holding?
Promoters held 57.48% of Cohance Lifesciences on 30 September 2026, down 0.01 percentage points from 57.49% the previous quarter and down 0.01 percentage points from 57.49% a year earlier, according to the shareholding pattern filed with NSE.
What is the Cohance Lifesciences free cash flow?
In FY26, Cohance Lifesciences generated ₹368 crore of cash from operations and spent ₹220 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹148 crore. In FY25 it was ₹132 crore.
What is the Cohance Lifesciences shareholding pattern?
On 30 September 2026, Cohance Lifesciences' shares were held by promoters 57.48%, foreign portfolio investors (FII/FPI) 7.71%, domestic institutions (DII) 18.86% (including mutual funds at 16.93%) and retail and other non-institutional investors 15.95%. Over the year, FII holding was up 1.20 percentage points from 6.51% and DII holding was down 1.96 percentage points from 20.82%.
What are the Cohance Lifesciences latest quarterly results?
Cohance Lifesciences' latest results are for Q1 FY27 (April–June 2026), filed on 5 August 2026: consolidated net loss ₹24.1 crore, against a profit of ₹48.9 crore in Q1 FY26; revenue from operations ₹422 crore, down 23.1% year on year.
How does the Cohance Lifesciences PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Cohance Lifesciences' PE ratio is 102.8, the highest of the four: Divi's Labs 99.7, Syngene International 50.8 and Aster DM Healthcare 90.7, a peer average of 80.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the Cohance Lifesciences revenue and profit in FY26?
In FY26 (April 2025–March 2026), Cohance Lifesciences' consolidated net profit attributable to shareholders was ₹179 crore, down 33.1% from ₹268 crore in FY25, on revenue from operations of ₹2,269 crore (up 89.4%). Over three years, from FY23, net profit was down 56.4%.
How does Cohance Lifesciences compare with its peers?
On FY26 consolidated figures, against Divi's Labs, Syngene International and Aster DM Healthcare: Cohance Lifesciences' operating margin of 10.6% is the lowest of the four (Divi's Labs 28.2%, Syngene International 12.5%, Aster DM Healthcare 13.7%; peer average 18.1%); its return on equity of 6.4% is the lowest of the four (Divi's Labs 16.2%, Syngene International 6.6%, Aster DM Healthcare 9.7%; peer average 10.8%); its revenue growth over three years of 19.2% a year is the highest of the four (Divi's Labs 10.8% a year, Syngene International 5.4% a year, Aster DM Healthcare −27.0% a year; peer average −3.6% a year).
Cohance Lifesciences vs Divi's Labs: how do they compare?
In FY26, Cohance Lifesciences earned net profit attributable to shareholders of ₹179 crore on revenue of ₹2,269 crore, against ₹2,568 crore on ₹10,560 crore for Divi's Labs. Cohance Lifesciences' operating margin was 10.6% (Divi's Labs 28.2%) and its return on equity 6.4% (Divi's Labs 16.2%). At the 29 October 2026 close, Cohance Lifesciences' market capitalisation was ₹18,416 crore against ₹2,56,096 crore for Divi's Labs, and its PE ratio on FY26 profit 102.8 against 99.7.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
